Raymond Kaempfer
Corporate Officer/Principal chez European Molecular Biology Organization
Profil
Raymond Kaempfer was the founder of Atox Bio Ltd., which was founded in 2003, where he held the title of Chief Scientific Officer from 2003 to 2011.
He is currently a Member of the European Molecular Biology Organization.
Dr. Kaempfer's former positions include being a Faculty Member at Harvard University and a Professor of Molecular Biology & Cancer Research at The Hebrew University of Jerusalem.
Dr. Kaempfer received a doctorate degree from the Massachusetts Institute of Technology.
Postes actifs de Raymond Kaempfer
| Sociétés | Poste | Début |
|---|---|---|
| European Molecular Biology Organization | Corporate Officer/Principal | - |
Anciens postes connus de Raymond Kaempfer
| Sociétés | Poste | Fin |
|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Fondateur | - |
Formation de Raymond Kaempfer
| Massachusetts Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Health Technology |
| European Molecular Biology Organization |